Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease

Table 1 Treatments included in the study

Treatment	Dose	Mode of administration
GLY via the eFlow CS nebulizer^a	50 μg	Electronic nebulizer
GLY via the eFlow CS nebulizer^a with activated charcoal	50 μg	Electronic nebulizer
GLY via DPI^b	63 μg	DPI
GLY via DPI^b with activated charcoal	63 μg	DPI
GLY sterile solution^c	50 μg	5-min IV infusion

CS closed system, DPI dry powder inhaler, GLY glycopyrronium bromide, IV intravenous
^aThe dose for nebulized GLY was 50 μg per ampule
^bThe dose for GLY inhalation powder was 63 μg per capsule
^cThe IV dose was 50 μg (0.25 mL from the 200 μg/mL injection vial)

ISSN: 1465-993X